Skip to main content
. 2020 Dec 13;6(3):830–834. doi: 10.1016/j.ekir.2020.11.040

Table 3.

Treatments and outcomes of patients with AICN

Patient no. AMX arrest Volume expansion Solutes Double J catheterization AMX rechallenge Delay of reintroduction, days RRT Return of baseline sCr before discharge Delay between recovery and AMX arrest, days sCr on discharge, mg/dl Length of follow-up, days Last sCr, mg/dl Last eGFR, ml/min/1.73 m2
1 1 0 0 0 0 1 8 0.73 184 0.9 66
2 1 1 Crystalloids 1 0 0 0 23 1.46 287 0.6 103
3 1 1 Crystalloids/oral sodium bicarbonate intake 0 1 7 0 1 3 0.86 0 0.86 67
4 1 1 Oral sodium bicarbonate intake 0 1 7 0 1 1 NA 3 1.1 51
5 1 1 Crystalloids 0 1 0 1 0 3.4 68 0.86 92
6 1 NA NA 0 0 0 1 5 NA 128 0.48 136
7 1 NA NA 1 0 0 1 8 NA 602 0.58 119
8 1 1 Crystalloids/HCO3 Na 1.4% 0 0 0 1 14 2.14 305 0.71 83
9 1 1 Ringer lactate 0 1 19 0 1 18 0.97 171 0.62 130
10 1 1 Crystalloids/HCO3 Na 1.4% 0 0 0 1 2 0.53 0 0.53 130

AICN, amoxicillin-induced crystal nephropathy; AMX, amoxicillin; sCr, serum creatinine; eGFR, estimated glomerular filtration rate by modification of diet in renal disease equation; NA, not available; RRT, renal replacement therapy.